FDA Investigator James B Arnett
James B Arnett has conducted inspections on 6 sites in 1 countries as of 01 Mar 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
6
Last Inspection Date:
01 Mar 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with James B Arnett:
Alan L Truong,
Amanda L Fyles,
Amir Alavi,
Ashar P Parikh,
Bichsa T Tran,
Binh T Nguyen,
Carla J Lundi,
Carolina D Vasquez,
Carrie A Hughes,
Caryn M Mcnab,
Cecilia H Kieu,
Crystal Monroy,
David Serrano,
Diane R Weidley,
Dogbeda F Mackenzie,
Elizabeth Ad Girard,
Heidy C Perales,
Himanshu Gupta, PhD,
Homero W Aguilar,
Hossein Khorshidi, PhD,
Iris C Macinnes,
Jacob G Lutz,
James R Fleckenstein,
Jeffrey P Raimondi,
Jennifer M Gogley,
Jinnie Kokiatkulkij,
Joan M Cantellops Figueroa,
Joel D Hustedt,
Joey V Quitania,
John A Gonzalez,
Jolanna A Norton,
Kham Phommachanh,
Kim Lthomas Cruse,
Kristin M Abaonza,
Lakecha N Lewis,
Lillian S Wu,
Lilly O Barton,
Ling Yu L Liu,
Marcus F Yambot,
Mark C Saale,
Mark W Babbitt,
Melanie M Walker,
Michael T Cyrus,
Nicholas L Hunt,
Philip F Istafanos, DMV, MS,
Rachel C Stanton,
Robert C Coleman,
Sandra L Shire, DMD, MPA,
Sangeeta M Khurana, PhD,
Santiago Gallardo Johnson,
Sonya L Karsik, RAC,
Srinivas R Chennamaneni, PhD,
Sue Lee Chan,
Taichun Qin, PhD,
Tamala P Bogan,
Tamala P Magee,
Timothy T Kapsala,
Truong Xuan Nguyen (Andy),
Uttaniti Limchumroon (Tom),
Virgilio F Pacio, CSO,
Walden H Lee,
Xiaohui Shen,
Yvonne Y Wu
James B Arnett's Documents
Publish Date | Document Type | Title |
---|---|---|
April, 2022 | FDA 483 | Lynn Oaks Compounding Pharmacy - Form 483, 2022-04-15 |
December, 2021 | EIR | Gilead Sciences, Inc. - EIR, 2021-12-17 |
December, 2021 | FDA 483 | Gilead Sciences, Inc. - Form 483, 2021-12-17 |
March, 2022 | FDA 483 | AIRGAS USA, LLC - Form 483, 2022-03-11 |
July, 2021 | FDA 483 | Enemeez, LLC dba Summit Pharmaceuticals - Form 483, 2021-07-29 |
October, 2021 | FDA 483 | TG Labs, Inc. - Form 483, 2021-10-29 |
June, 2021 | FDA 483 | Amphastar Pharmaceuticals, Inc. - Form 483, 2021-06-22 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more